Cargando…
非小细胞肺癌T790M基因突变研究进展
Patients with advanced non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) activating mutations benefit from EGFR-tyrosine kinase inhibitor (TKI) treatment, however, most of TKI-treated patients eventually suffer drug resistant after 10-month treatments. Previous stud...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000573/ https://www.ncbi.nlm.nih.gov/pubmed/23769347 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.08 |